A Sensitive Fluorescence Assay of Serum Dipeptidyl Peptidase IV Activity to Predict the Suitability of its Inhibitors in Patients with Type 2 Diabetes Mellitus

Published: Jan. 1, 2024

DPP-IV inhibitors, which are close to the natural hypoglycemic pathway of human physiology and have few side effects, been extensively employed in management type 2 diabetes mellitus (T2DM). However, there currently no specific blood indicators that can indicate or predict a patient's suitability for inhibitors. In this study, based on self-developed high-specificity fluorescent substrate glycyl-prolyl-N-butyl-4-amino-1, 8-naphthimide (GP-BAN), detection method serum activity was established optimized. The demonstrates favorable lower limit (LOD) at 0.32 ng/mL satisfactory quantification (LOQ) 1.12 ng/mL, be used trace (2μL). addition, Vitalliptin Sitagliptin showed similar IC50 values when recombinant were as enzyme sources, intra-day inter-day precision obtained by microplate analyzer less than 15%. These results reader technique has good accuracy, repeatability reproducibility. A total 700 volunteers recruited, 646 samples tested activity. higher patients with T2DM controls (P < 0.01). statistical data family history diabetes, gender age diabetic significance, contrast difference. ranged from 2.4 μmol/min/L 78.6 μmol/min/L, huge difference up 32-fold. suggest it is necessary test taking inhibitors determine applicability patients. detect before judge T2DM.

Language: Английский

A sensitive fluorescence assay of serum dipeptidyl peptidase IV activity to predict the suitability of its inhibitors in patients with type 2 diabetes mellitus

Journal of Pharmaceutical and Biomedical Analysis, Journal Year: 2024, Volume and Issue: 249, P. 116382 - 116382

Published: July 26, 2024

Language: Английский